Efficacy of 3% Hypertonic Saline in Acute Viral Bronchiolitis (GUERANDE)
The purpose of this study is to determine whether nebulized hypertonic saline solution reduces the admission rate 48 hours after initial treatment in the emergency department, when compared to normal saline solution (control).
Acute Viral Bronchiolitis
Drug: 3% Saline
Drug: 0.9% Normal Saline
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||3% Hypertonic Saline to Reduce Hospitalization Rate in Acute Viral Bronchiolitis: a Randomized Double Blind Clinical Trial|
- Admission rate [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
- change in RDAI score [ Time Frame: 2 hours ] [ Designated as safety issue: No ]
- Number of Participants with Adverse Events [ Time Frame: 2 hours ] [ Designated as safety issue: Yes ]
- length of hospitalization for hospitalized infant [ Time Frame: 1 month ] [ Designated as safety issue: No ]
- health care utilisation [ Time Frame: 1 month ] [ Designated as safety issue: No ]
|Study Start Date:||October 2012|
|Study Completion Date:||April 2014|
|Primary Completion Date:||April 2014 (Final data collection date for primary outcome measure)|
Experimental: 3% Saline
Nebulized 3% Saline
Drug: 3% Saline
Two 4 mL nebulization of 3% saline with 20 minutes interval
Other Name: 3% Hypertonic Saline Solution for Inhalation (Mucoclear 3%)
Placebo Comparator: 0.9% Normal Saline
Nebulized 0.9% normal saline
Drug: 0.9% Normal Saline
Two 4 mL nebulization of 0.9% normal saline with 20 minutes interval
Other Name: 0.9% Saline Solution for Inhalation
Acute viral bronchiolitis remains a significant cause of hospitalization and to date, no treatment reduce the rate of hospitalization. The only accepted treatment for bronchiolitis is nasal cleaning, hydration and for hospitalized hypoxemic infants, oxygen administration.
Several studies shown that nebulization of hypertonic saline solution reduce length of stay in hospital for hospitalized infant but effect on rate of hospitalization remains unclear.
The investigators propose a randomized double blind multicenter clinical trial on infants 6 weeks to 12 months old with moderate or severe bronchiolitis, in 21 emergency departments of hospitals situated France, during 2 winter seasons.
The investigators hypothesize that infants with bronchiolitis treated with nebulized hypertonic 3% saline solution would have less risk of being hospitalized. Our principal objective is to determine if nebulized 3% hypertonic saline solution reduces admission rate 24 hours after treatment compared to placebo.
Secondary objectives are to compare between groups intensity of respiratory symptoms measured by RDAI clinical score, duration of symptoms, length of hospital stay for hospitalized infants, adverse effects and health care utilization.
Patients presenting to the Emergency Department with a diagnosis of moderately severe bronchiolitis will be approached for entry into the study. After the initial routine assessment, informed consent will be obtained and the infant will be randomized to receive treatment in a double-blinded fashion 4 ml of nebulized study solution either 3% hypertonic saline (HS, study group) or 0.9% saline (NS, control group) every 20 minutes for a total of 2 doses. After an observation period of 20 minutes following the last dose, the infant will be reassessed by the attending physician in the ER for disposition (admit, discharge home). All subsequent therapy, if needed, will be at the sole discretion of the attending physician. The family of each recruited subject will be contacted by phone 2, 7, 14 and 28 days later to assess resolution of symptoms.
Clinical response to the above treatment will also be determined independently by the study physician utilizing a standardized respiratory scoring system, the Respiratory Distress Assessment Instrument (RDAI), at study entry and after each nebulization. The primary outcome measure is the rate of admission to hospital between the study and control groups 24 hours after inclusion. Secondary outcomes measure will involve the assessment of change in the RDAI between study entry and post-treatment, adverse effects, length of stay for hospitalized infant and health care utilization.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01777347
|Hôpital Jean Verdier|
|Bondy, France, 93140|
|Hôpital Ambroise Paré|
|Boulogne, France, 92100|
|Hôpital Antoine Béclère|
|Clamart, France, 92141|
|Hôpital Louis Mouriez|
|Centre Hospitalier Sud Francilien|
|Corbeil, France, 91100|
|Centre Hospitalier intercommunal de Créteil|
|Créteil, France, 94000|
|Centre Hospitalier de Fontainebleau|
|Fontainebleau, France, 77305|
|Hôpital Kremlin Bicêtre|
|Le Kremlin Bicêtre, France|
|Hôpital Jeanne de Flandre|
|Hôpital Hôpital Mère Enfants|
|Hôpital Hôpital Femme Mère Enfants|
|Hôpital Mère - Enfants|
|Hôpital Necker-Enfants Malades|
|Paris, France, 75007|
|Hôpital Robert Debré|
|Paris, France, 75019|
|Hôp Charles Nicolle - CHU Rouen|
|Rouen, France, 76000|
|Hôpital des enfants|
|Principal Investigator:||Vincent Gajdos, MD, PhD||Assistance Publique Hôpitaux de Paris - Paris Sud Medical School|